^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    umitrelimorgene autodencel (ITI-1000)

    i
    Associations

    News

    Trials
    Company:
    HLB Bio Group
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. (clinicaltrials.gov)
    P1, N=6, Terminated, University of Florida | N=10 --> 6 | Trial completion date: May 2025 --> Sep 2023 | Active, not recruiting --> Terminated; Terminated by mutual agreement by sponsor and institution.
    Enrollment change • Trial completion date • Trial termination
    |
    temozolomide • umitrelimorgene autodencel (ITI-1000)
    over1year
    RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, University of Florida
    Trial completion date • Trial primary completion date
    |
    temozolomide • umitrelimorgene autodencel (ITI-1000)
    over1year
    ATTAC II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=175, Completed, University of Florida | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Nov 2023 | Trial primary completion date: Sep 2024 --> Nov 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    temozolomide • umitrelimorgene autodencel (ITI-1000)
    over1year
    ATTAC II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=175, Active, not recruiting, University of Florida | Trial completion date: Sep 2024 --> Sep 2026
    Trial completion date
    |
    IL2 (Interleukin 2)
    |
    temozolomide • umitrelimorgene autodencel (ITI-1000)
    over1year
    ATTAC II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=175, Active, not recruiting, Immunomic Therapeutics, Inc. | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    temozolomide • umitrelimorgene autodencel (ITI-1000)
    2years
    ATTAC II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=175, Active, not recruiting, Immunomic Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IL2 (Interleukin 2)
    |
    temozolomide • umitrelimorgene autodencel (ITI-1000)
    over3years
    ATTAC-II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=175, Recruiting, Immunomic Therapeutics, Inc. | N=120 --> 175
    Clinical • Enrollment change
    |
    IL2 (Interleukin 2)
    |
    temozolomide • umitrelimorgene autodencel (ITI-1000)